Galapagos Buys ProSkelia for $16.4M; Corrals $40.7M in Financing | GenomeWeb
NEW YORK (GenomeWeb News) - Galapagos said today that it has entered an agreement to buy drug-discovery firm ProSkelia for €12.5 million ($16.4 million) in stock.
 
Galapagos also said it has raised €31 million ($40.7 million) in financing through the private placement of new shares to institutional investors in Europe and the US. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.